Rotkreuz, 16 May 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will be showcasing innovative laboratory solutions and discussing the future of digital diagnostics at the 23rd IFCC–EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EuroMedLab) in Barcelona, Spain (19-23 May). Attendees will have the opportunity to experience first-hand Roche’s latest technological advancements in lab automation, such as the newly launched cobas® pro integrated solutions, and find out more about their vision for transforming patient care through advancements in breakthrough diagnostic solutions.
“With signs of unprecedented change in healthcare delivery, labs and clinicians are expected to manage an increasingly high number of samples, deliver results more efficiently while improving patient outcomes,” said Thomas Schinecker, Global Head of Centralised and Point of Care Solutions, Roche Diagnostics. "That is why we continuously deliver innovative solutions that support clinical decision making based on medical needs."
At the congress, Roche will be holding discussions on healthcare transformation and the role that digitalisation can play in transforming how patient care is delivered. With their integrated digital solutions such as the NAVIFY® Decision Support apps and the acquisition of Viewics, Inc., Roche is leading the way with laboratory business analytics that increase productivity, decision-making and clinical care for laboratories and hospitals.
“Today, in vitro diagnostics influence up to 70% of all clinical decisions¹,²,” said Youssef Khayali, Head of Integrated Diagnostics & Healthcare Solutions. "With our portfolio of innovative solutions, Roche is uniquely positioned to lead the way partnering with labs to create more value and simplify operations through end-to-end lab automation, technology and digital solutions."
To experience other advancements in digital technology, attendees will have the opportunity to visit Roche Diagnostics’ state-of-the-art booth. The booth will feature advancements in the connectivity of the integrated core lab; new digital diagnostics solutions; and ‘In-Booth Talks’ presented by customers and Roche representatives on various medical and economic value topics.
Highlights of Roche Diagnostics at EuroMedLab:
Monday 20 May, 12:30–13:30
EduW4: Applied use of digital solutions in laboratory medicine
Chair: Professor Philip Quirke, University of Leeds, UK
Challenges and opportunities for a large automation laboratory to build the digital future
Dr. Emerson Gaspareto, CMO Dasa, Brazil
Implementation of a digital ecosystem to develop clinical algorithms
Professor Philip Quirke, Leeds, UK
Tuesday 21 May, 12:30–13:30
EduW19: Evidence based value care delivery
Chair: Dr. Antonio Leon Justel, Hospital Virgen Macarena, Spain
Lucien Engelen, Director REshape Center, Radboud umc, Netherlands
Value based innovation in heart failure patient management
Dr. Antonio Leon Justel, Hospital Virgen Macarena, Spain
Wednesday 22 May, 12:30–13:30
EduW21: Integration of lab results into the diagnostic pathway
Chair: Professor Dr. med. Luca Giovanella, Centre for Thyroid Diseases, Switzerland
Immunoassay Interferences: Facts, insights and a pragmatic approach
Nam K. Tran, PhD, HCLD (ABB), FACB, UC Davis, USA
The clinician’s approach to immunoassay results
Professor Dr. med. Luca Giovanella, Centre for Thyroid Diseases, Switzerland
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.